{"success":true,"data":{"pressRelease":{"id":"168118","rtpr_id":"nGNX3Gj1Hy-20261013","ticker":"LKFT","exchange":"Euronext Amsterdam","all_tickers":["LKFT"],"title":"Acquisition of Own Shares","author":"Globe Newswire","published_at":"2026-10-13T20:01:00.454Z","article_body":"Mechelen, Belgium; October 13, 2026, 22.01 CET; regulated information\n\nWithin the framework of the repurchase program announced on June 9, 2026,\nLakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) (\"Lakefront\") announces\nthat between October 05, 2026 and October 09, 2026 it has repurchased 126,322\nLakefront shares via a discretionary mandate to an independent financial\nintermediary, as follows:\n\n Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) \n 10/5/2026 XAMS 20,641 26.14 539,466.98 25.78 26.50 \n 10/5/2026 TQEX 442 26.01 11,497.92 25.90 26.04 \n 10/5/2026 CEUX 2,656 25.97 68,975.52 25.82 26.22 \n 10/5/2026 AQEU 174 25.88 4,503.12 25.88 25.88 \n 10/6/2026 XAMS 20,421 26.40 539,130.74 25.94 26.64 \n 10/6/2026 TQEX 1,383 26.54 36,708.97 26.20 26.64 \n 10/6/2026 CEUX 2,620 26.51 69,458.30 26.42 26.64 \n 10/6/2026 AQEU 679 26.59 18,051.55 26.44 26.64 \n 10/7/2026 XAMS 22,325 26.15 583,776.43 25.86 26.54 \n 10/7/2026 CEUX 2,566 26.16 67,136.05 25.90 26.48 \n 10/7/2026 AQEU 506 26.18 13,246.17 26.00 26.50 \n 10/8/2026 XAMS 22,557 26.20 591,027.24 25.82 26.78 \n 10/8/2026 TQEX 150 26.27 3,940.01 26.24 26.34 \n 10/8/2026 CEUX 2,158 26.27 56,690.44 26.20 26.36 \n 10/8/2026 AQEU 817 26.20 21,408.91 26.20 26.22 \n 10/9/2026 XAMS 21,498 26.40 567,643.94 26.18 26.66 \n 10/9/2026 TQEX 592 26.38 15,616.60 26.34 26.46 \n 10/9/2026 CEUX 3,394 26.37 89,516.07 26.34 26.44 \n 10/9/2026 AQEU 743 26.40 19,612.97 26.34 26.46 \n Total 126,322 26.26 3,317,407.94 25.78 26.78 \n\nAs of market close on October 9, 2026, Lakefront holds 1,877,353 of its own\nordinary shares.\n\nAbout Lakefront Biotherapeutics\nLakefront Biotherapeutics is a biotechnology company dedicated to building a\ndifferentiated pipeline of medicines for patients with serious diseases in\nareas of high unmet need. The Company has established a clinical‑stage\nportfolio in immunology and inflammation, anchored by gamgertamig, a potential\nfirst‑in‑class and best-in-class BCMAxCD3 T‑cell engager for autoimmune\ndiseases. Backed by deep deal‑making expertise, operational flexibility, and\na strong capital position, Lakefront identifies, acquires, and advances\nhigh‑quality assets with clear potential to deliver meaningful patient\nimpact and long‑term shareholder value. For more information, visit\nhttps://www.lakefrontbio.com or follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=ZPzDrp2o8PkN6Do-X55Svo8GMtucna2qChZzleznOrxBlDiwbmeDU29BLhci0DA34gun-2qRpRWTCxX3dOYj-QkjbojEhKQY9Cz_bThY2F8PT_gCdhkKgaaL34SFdEic)\nor X\n(https://www.globenewswire.com/Tracker?data=5SnmVPVvChYL-VaEOcOsFSHhpwBkVqOQ7P2GS2hvAHQFYfeGnvuQqnNj522H6ZPaXY0PwSDA3NmZyy5wcv0org==).\n\nFor further information, contact Lakefront Biotherapeutics:\nInvestor Relations \nSherri Spear\n+1 412 522 6418\nsherri.spear@lakefrontbio.com\n\nRichie Livingston\n+1 312 636 7072\nrichie.livingston@lakefrontbio.com\n\nForward-looking statements\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, all of which involve\ncertain risks and uncertainties. These statements are often, but are not\nalways, made through the use of words or phrases such as “believe,”\n“anticipate,” “expect,” “intend,” “plan,” “seek,”\n“upcoming,” “future,” “estimate,” “may,” “will,”\n“could,” “would,” “potential,” “forward,” “goal,”\n“next,” “continue,” “should,” “encouraging,” “aim,”\n“progress,” “remain,” “explore,” and “further,” as well as\nsimilar expressions. These statements include, but are not limited to,\nstatements regarding Lakefront’s plans to repurchase its ordinary shares.\nLakefront cautions the reader that forward-looking statements are based on our\nmanagement’s current expectations and beliefs and are not guarantees of\nfuture performance. Forward-looking statements may involve known and unknown\nrisks, uncertainties and other factors which might cause actual events,\nfinancial condition and liquidity, performance, or achievements, or the\nindustry in which we operate, to be materially different from any historic or\nfuture results, financial conditions, performance or achievements expressed or\nimplied by such forward-looking statements. In addition, even if our results,\nperformance, financial condition and liquidity, and the development of the\nindustry in which Lakefront operates are consistent with such forward-looking\nstatements, they may not be predictive of results or developments in future\nperiods. Such risks include, but are not limited to, those risks and\nuncertainties that can be found in our filings and reports with the Securities\nand Exchange Commission (“SEC”), including in our most recent annual\nreport on Form 20-F filed with the SEC and our subsequent filings and reports\nfiled with the SEC. Given these risks and uncertainties, the reader is advised\nnot to place any undue reliance on such forward-looking statements. In\naddition, even if the result of our operations, financial condition and\nliquidity, or the industry in which we operate, are consistent with such\nforward-looking statements, they may not be predictive of results, performance\nor achievements in future periods. These forward-looking statements speak only\nas of the date of publication of this release. We expressly disclaim any\nobligation to update any such forward-looking statements in this release to\nreflect any change in our expectations or any change in events, conditions or\ncircumstances, unless specifically required by law or regulation.\n\nAttachment\n* 20261009 LakefrontEN RNS Announcement\n(https://ml-eu.globenewswire.com/Resource/Download/4072545c-579a-491e-821d-d13b6f7f1d58)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/5100317d-9c26-4bbc-9bcc-dd77343f5f96)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX3Gj1Hy-20261013","title":"Acquisition of Own Shares","author":"Globe Newswire","ticker":"LKFT","created":"2026-10-13T20:01:00.454Z","tickers":["LKFT"],"exchange":"Euronext Amsterdam","article_body":"Mechelen, Belgium; October 13, 2026, 22.01 CET; regulated information\n\nWithin the framework of the repurchase program announced on June 9, 2026,\nLakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) (\"Lakefront\") announces\nthat between October 05, 2026 and October 09, 2026 it has repurchased 126,322\nLakefront shares via a discretionary mandate to an independent financial\nintermediary, as follows:\n\n Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) \n 10/5/2026 XAMS 20,641 26.14 539,466.98 25.78 26.50 \n 10/5/2026 TQEX 442 26.01 11,497.92 25.90 26.04 \n 10/5/2026 CEUX 2,656 25.97 68,975.52 25.82 26.22 \n 10/5/2026 AQEU 174 25.88 4,503.12 25.88 25.88 \n 10/6/2026 XAMS 20,421 26.40 539,130.74 25.94 26.64 \n 10/6/2026 TQEX 1,383 26.54 36,708.97 26.20 26.64 \n 10/6/2026 CEUX 2,620 26.51 69,458.30 26.42 26.64 \n 10/6/2026 AQEU 679 26.59 18,051.55 26.44 26.64 \n 10/7/2026 XAMS 22,325 26.15 583,776.43 25.86 26.54 \n 10/7/2026 CEUX 2,566 26.16 67,136.05 25.90 26.48 \n 10/7/2026 AQEU 506 26.18 13,246.17 26.00 26.50 \n 10/8/2026 XAMS 22,557 26.20 591,027.24 25.82 26.78 \n 10/8/2026 TQEX 150 26.27 3,940.01 26.24 26.34 \n 10/8/2026 CEUX 2,158 26.27 56,690.44 26.20 26.36 \n 10/8/2026 AQEU 817 26.20 21,408.91 26.20 26.22 \n 10/9/2026 XAMS 21,498 26.40 567,643.94 26.18 26.66 \n 10/9/2026 TQEX 592 26.38 15,616.60 26.34 26.46 \n 10/9/2026 CEUX 3,394 26.37 89,516.07 26.34 26.44 \n 10/9/2026 AQEU 743 26.40 19,612.97 26.34 26.46 \n Total 126,322 26.26 3,317,407.94 25.78 26.78 \n\nAs of market close on October 9, 2026, Lakefront holds 1,877,353 of its own\nordinary shares.\n\nAbout Lakefront Biotherapeutics\nLakefront Biotherapeutics is a biotechnology company dedicated to building a\ndifferentiated pipeline of medicines for patients with serious diseases in\nareas of high unmet need. The Company has established a clinical‑stage\nportfolio in immunology and inflammation, anchored by gamgertamig, a potential\nfirst‑in‑class and best-in-class BCMAxCD3 T‑cell engager for autoimmune\ndiseases. Backed by deep deal‑making expertise, operational flexibility, and\na strong capital position, Lakefront identifies, acquires, and advances\nhigh‑quality assets with clear potential to deliver meaningful patient\nimpact and long‑term shareholder value. For more information, visit\nhttps://www.lakefrontbio.com or follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=ZPzDrp2o8PkN6Do-X55Svo8GMtucna2qChZzleznOrxBlDiwbmeDU29BLhci0DA34gun-2qRpRWTCxX3dOYj-QkjbojEhKQY9Cz_bThY2F8PT_gCdhkKgaaL34SFdEic)\nor X\n(https://www.globenewswire.com/Tracker?data=5SnmVPVvChYL-VaEOcOsFSHhpwBkVqOQ7P2GS2hvAHQFYfeGnvuQqnNj522H6ZPaXY0PwSDA3NmZyy5wcv0org==).\n\nFor further information, contact Lakefront Biotherapeutics:\nInvestor Relations \nSherri Spear\n+1 412 522 6418\nsherri.spear@lakefrontbio.com\n\nRichie Livingston\n+1 312 636 7072\nrichie.livingston@lakefrontbio.com\n\nForward-looking statements\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, all of which involve\ncertain risks and uncertainties. These statements are often, but are not\nalways, made through the use of words or phrases such as “believe,”\n“anticipate,” “expect,” “intend,” “plan,” “seek,”\n“upcoming,” “future,” “estimate,” “may,” “will,”\n“could,” “would,” “potential,” “forward,” “goal,”\n“next,” “continue,” “should,” “encouraging,” “aim,”\n“progress,” “remain,” “explore,” and “further,” as well as\nsimilar expressions. These statements include, but are not limited to,\nstatements regarding Lakefront’s plans to repurchase its ordinary shares.\nLakefront cautions the reader that forward-looking statements are based on our\nmanagement’s current expectations and beliefs and are not guarantees of\nfuture performance. Forward-looking statements may involve known and unknown\nrisks, uncertainties and other factors which might cause actual events,\nfinancial condition and liquidity, performance, or achievements, or the\nindustry in which we operate, to be materially different from any historic or\nfuture results, financial conditions, performance or achievements expressed or\nimplied by such forward-looking statements. In addition, even if our results,\nperformance, financial condition and liquidity, and the development of the\nindustry in which Lakefront operates are consistent with such forward-looking\nstatements, they may not be predictive of results or developments in future\nperiods. Such risks include, but are not limited to, those risks and\nuncertainties that can be found in our filings and reports with the Securities\nand Exchange Commission (“SEC”), including in our most recent annual\nreport on Form 20-F filed with the SEC and our subsequent filings and reports\nfiled with the SEC. Given these risks and uncertainties, the reader is advised\nnot to place any undue reliance on such forward-looking statements. In\naddition, even if the result of our operations, financial condition and\nliquidity, or the industry in which we operate, are consistent with such\nforward-looking statements, they may not be predictive of results, performance\nor achievements in future periods. These forward-looking statements speak only\nas of the date of publication of this release. We expressly disclaim any\nobligation to update any such forward-looking statements in this release to\nreflect any change in our expectations or any change in events, conditions or\ncircumstances, unless specifically required by law or regulation.\n\nAttachment\n* 20261009 LakefrontEN RNS Announcement\n(https://ml-eu.globenewswire.com/Resource/Download/4072545c-579a-491e-821d-d13b6f7f1d58)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/5100317d-9c26-4bbc-9bcc-dd77343f5f96)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-13T20:01:00.511402626Z","server_sent_at_ms":1791921660511},"received_at":"2026-10-13T20:01:00.562Z","source_url":null},"analysis":{"id":"156396","press_release_id":"168118","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"buyback","narrative":"Lakefront Biotherapeutics repurchased 126,322 of its own shares between October 5 and October 9, 2026, at an average price of €26.26 for a total of about €3.32 million.\n\nThe purchases were executed via a discretionary mandate to an independent financial intermediary under the buyback program announced on June 9, 2026.\n\nAs of the October 9 market close, Lakefront holds 1,877,353 of its own ordinary shares.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine weekly buyback execution under existing June 2026 program — no new authorization."},"keyFigures":{"customDimensions":{"avg_price_paid_eur":26.26,"total_own_shares_held":1877353,"shares_repurchased_week":126322}},"namedEntities":{"people":[{"name":"Sherri Spear","role":"Investor Relations"},{"name":"Richie Livingston","role":"Investor Relations"}],"products":["gamgertamig"],"companies":[{"name":"Lakefront Biotherapeutics NV","ticker":"LKFT"}],"dollarAmounts":[{"amount":"3,317,407.94","context":"total spent repurchasing 126,322 shares during week of Oct 5-9, 2026"}]},"materialImpact":{"score":2,"reasoning":"Routine weekly disclosure of buyback execution under an existing program announced June 9, 2026. Repurchases of €3.3M are modest and not a new authorization."},"tickerRelevance":{"others":[],"primary":"LKFT"},"globalImportance":12,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine buyback progress disclosure","issuerAuthored":true}},"event_type":"buyback","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Lakefront Biotherapeutics repurchased 126,322 of its own shares between October 5 and October 9, 2026, at an average price of €26.26 for a total of about €3.32 million.\n\nThe purchases were executed via a discretionary mandate to an independent financial intermediary under the buyback program announced on June 9, 2026.\n\nAs of the October 9 market close, Lakefront holds 1,877,353 of its own ordinary shares.","key_figures":{"customDimensions":{"avg_price_paid_eur":26.26,"total_own_shares_held":1877353,"shares_repurchased_week":126322}},"named_entities":{"people":[{"name":"Sherri Spear","role":"Investor Relations"},{"name":"Richie Livingston","role":"Investor Relations"}],"products":["gamgertamig"],"companies":[{"name":"Lakefront Biotherapeutics NV","ticker":"LKFT"}],"dollarAmounts":[{"amount":"3,317,407.94","context":"total spent repurchasing 126,322 shares during week of Oct 5-9, 2026"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-13T20:01:04.069Z","global_importance":12,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine buyback progress disclosure","issuerAuthored":true}},"durationMs":3471,"modelName":"glm-5.3-flashx"}}